Workflow
KHB(002022)
icon
Search documents
AI医疗再迎政策催化,建信中证全指医疗保健设备与服务ETF(159891)跟踪指数拉升涨超2%,成分股赛诺医疗20%涨停
Xin Lang Cai Jing· 2025-08-07 06:23
Core Viewpoint - The healthcare equipment and services sector is experiencing a significant boost, driven by policy support for AI in healthcare, with notable stock price increases among key companies in the industry [1] Group 1: Market Performance - As of August 7, 2025, the CSI All Index for Healthcare Equipment and Services (H30178) rose over 2%, currently up by 1.00% [1] - Key stocks such as Diedeman (300289) increased by 20.02%, Sainuo Medical (688108) by 20.01%, and Zhonghong Medical (300981) by 19.99% [1] Group 2: Policy Support - The State Council's executive meeting approved the "Artificial Intelligence+" action plan on July 31, indicating strong and clear policy support for AI applications in healthcare [1] - The AI applications in healthcare, particularly in AI pathology diagnosis, AI imaging, and AI pharmaceuticals, are expected to accelerate their commercialization process [1] Group 3: Industry Initiatives - On August 1, the National Healthcare Security Administration held a press conference to introduce the "Inviting Talents to Assist Medical Innovation" 2025 National Smart Healthcare Competition, marking the official launch of the competition [1] - The CCB CSI All Index for Healthcare Equipment and Services ETF (159891) closely tracks the CSI All Index for Healthcare Equipment and Services, reflecting the overall performance of listed companies in the healthcare sector [1]
医疗器械概念股震荡走高,尚荣医疗、科华生物双双涨停
Sou Hu Cai Jing· 2025-08-07 02:11
Core Viewpoint - The medical device sector is experiencing a significant upward trend, with multiple stocks reaching their daily limits, indicating strong investor interest and potential growth opportunities in the industry [1]. Group 1: Stock Performance - Medical device concept stocks are showing volatility with notable gains, including Shangrong Medical and Kehua Bio, both hitting the daily limit [1]. - Sino Medical also reached the daily limit during bidding, while Lideman and Zhonghong Medical increased by over 10% [1]. - Other companies such as Yangpu Medical, Nanwei Shares, BGI Genomics, and Kaili Medical saw increases of over 5% [1]. Group 2: Investment Opportunities - According to a report from CITIC Securities, future investment opportunities in the medical device sector are increasingly linked to internationalization [1]. - Several companies are expected to achieve high growth in their international business by 2025, with a continuous increase in the proportion of revenue from international operations [1]. - Companies with significant long-term potential in international business are likely to experience a revaluation of their stock prices [1].
科华生物股价上涨2.34% 艾滋病疫苗研发取得重要进展
Jin Rong Jie· 2025-08-04 17:15
Group 1 - The stock price of Kehua Bio reported at 7.00 yuan as of August 4, 2025, with an increase of 0.16 yuan, representing a rise of 2.34% compared to the previous trading day [1] - The trading volume on the same day was 307,075 hands, with a transaction amount reaching 212 million yuan [1] - Kehua Bio operates in the medical device industry, focusing on the research, production, and sales of in vitro diagnostic reagents and medical instruments [1] Group 2 - The company's product line includes various fields such as clinical biochemistry, immunodiagnostics, and molecular diagnostics [1] - A recent clinical trial for an HIV vaccine using the "Tian Tan strain" smallpox virus as a carrier has been completed, marking a significant development in the industry [1] - Industry experts anticipate that the HIV vaccine market will reach a commercialization turning point between 2025 and 2030, drawing market attention to Kehua Bio as a related concept stock [1] Group 3 - On August 4, Kehua Bio experienced a net outflow of main funds amounting to 3.1058 million yuan, which accounts for 0.09% of its circulating market value [1] - Over the past five trading days, the cumulative net outflow reached 19.6009 million yuan, representing 0.54% of its circulating market value [1]
科华生物股价下跌2.49% 公司聘任新财务总监
Jin Rong Jie· 2025-07-31 19:14
Core Viewpoint - KHBio's stock price closed at 6.66 yuan on July 31, reflecting a decrease of 0.17 yuan or 2.49% from the previous trading day [1] Group 1: Company Overview - KHBio operates in the medical device industry, focusing on the research, production, and sales of in vitro diagnostic reagents and medical instruments [1] - The company's product range includes clinical testing, immunodiagnostics, and molecular diagnostics [1] Group 2: Recent Developments - On July 31, KHBio's board approved the appointment of Zang Xianfeng as the new Chief Financial Officer [1] - The company announced that its ultra-high-performance liquid chromatography-tandem mass spectrometry system is an open system, which, when used with the company's mass spectrometry reagents, enhances the stability and accuracy of test results [1] - KHBio revealed a collaboration with Waters Corporation to launch two products that have received national medical device registration certificates, utilizing a "dual-brand" model to create an integrated platform [1] Group 3: Market Activity - On July 31, KHBio experienced a net outflow of main funds amounting to 17.06 million yuan, representing 0.5% of its circulating market value [1]
科华生物:聘任臧显峰为公司财务总监
Mei Ri Jing Ji Xin Wen· 2025-07-31 11:37
每经AI快讯,科华生物(SZ 002022)7月31日晚间发布公告称,罗芳女士因退休申请辞去公司财务总监 职务,同时一并辞去担任的公司下属子公司其他职务。公司审议通过了《关于聘任公司财务总监的议 案》,经公司总裁提名,董事会提名委员会、审计委员会审核,公司董事会同意聘任臧显峰先生为公司 财务总监。 截至发稿,科华生物市值为34亿元。 ST宁科:聘任金相宇为公司财务总监 宝馨科技徐业香辞去公司董事、财务总监职务 延江股份:聘任刘培源为公司财务总监 延伸阅读: 2024年1至12月份,科华生物的营业收入构成为:生物制品业占比100.0%。 ...
科华生物:公司与沃特世公司合作,提供双品牌高效液相色谱串联质谱整体解决方案
Zheng Quan Ri Bao Wang· 2025-07-31 09:46
证券日报网讯科华生物(002022)7月31日在互动平台回答投资者提问时表示,公司与沃特世公司 (Waters)合作,提供双品牌高效液相色谱串联质谱整体解决方案,涵盖系列设备及检测试剂,从孕前精 准病因筛查,孕期营养监测,到新生儿疾病防控,助力优生优育。敬请投资者防范概念炒作,理性投资 决策,注意投资风险。 ...
科华生物:控股子公司天隆公司基于荧光PCR技术平台开发的部分产品可辅助相关肿瘤筛查
Zheng Quan Ri Bao Wang· 2025-07-31 09:46
证券日报网讯科华生物(002022)7月31日在互动平台回答投资者提问时表示,公司基于免疫技术平台 开发的肝癌、胃癌、肺癌等相关肿瘤标志物检测试剂产品,搭配公司免疫技术平台通用检测仪器使用, 可用于肿瘤早期筛查和辅助诊断。此外,公司控股子公司天隆公司基于荧光PCR技术平台开发的部分产 品亦可辅助相关肿瘤筛查,如人乳头瘤病毒(HPV)检测试剂盒(荧光PCR法)可辅助诊断宫颈癌,EB病毒 检测试剂盒(荧光PCR法)可辅助诊断鼻咽癌等。 ...
科华生物(002022) - 关于变更公司财务总监的公告
2025-07-31 09:00
| 证券代码:002022 | 证券简称:科华生物 | 公告编号:2025-037 | | --- | --- | --- | | 债券代码:128124 | 债券简称:科华转债 | | 特此公告。 公司董事会对罗芳女士在任职期间为公司发展所做出的贡献表示衷心感谢! 二、公司聘任财务总监情况 公司于 2025 年 7 月 31 日召开第十届董事会第十四次会议,审议通过了《关 于聘任公司财务总监的议案》,经公司总裁提名,董事会提名委员会、审计委员 会审核,公司董事会同意聘任臧显峰先生为公司财务总监(简历附后),任期自 本次董事会审议通过之日起至第十届董事会任期届满之日止。 上海科华生物工程股份有限公司 关于变更公司财务总监的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 一、公司财务总监辞职情况 上海科华生物工程股份有限公司(以下简称"公司")董事会于近日收到公 司财务总监罗芳女士递交的书面辞职报告,罗芳女士因退休申请辞去公司财务总 监职务,同时一并辞去担任的公司下属子公司其他职务。罗芳女士担任财务总监 的原定任期至第十届董事会届满之日(2027 年 3 ...
科华生物(002022) - 第十届董事会第十四次会议决议公告
2025-07-31 09:00
证券代码:002022 证券简称:科华生物 公告编号:2025-036 债券代码:128124 债券简称:科华转债 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 上海科华生物工程股份有限公司(以下简称"公司")第十届董事会第十四 次会议(以下简称"本次会议"或"会议")通知于2025年7月30日以邮件方式送 达全体董事、监事及高级管理人员,会议于2025年7月31日以通讯表决的方式召 开。本次会议应参会董事9人,实际参会董事9人(包含3名独立董事)。本次会议 由公司董事长李明先生主持,会议的召开符合《中华人民共和国公司法》、《上海 科华生物工程股份有限公司章程》和《上海科华生物工程股份有限公司董事会议 事规则》的有关规定。 二、董事会会议审议情况 (一)审议通过《关于聘任公司财务总监的议案》 经公司总裁提名,董事会提名委员会、审计委员会审核,公司董事会同意聘 任臧显峰先生为公司财务总监,任期自本次董事会审议通过之日起至第十届董事 会任期届满之日止。 具体详见公司于同日在《证券时报》、《中国证券报》、《上海证券报》及巨潮 资讯网(htt ...
科华生物:公司在辅助生殖领域没有相关产品和业务,但在优生优育领域有相关诊断产品
Mei Ri Jing Ji Xin Wen· 2025-07-31 01:16
每经AI快讯,有投资者在投资者互动平台提问:公司在辅助生殖领域有相关产品或业务吗? 科华生物(002022.SZ)7月31日在投资者互动平台表示,公司在辅助生殖领域没有相关产品和业务,但 公司及子公司在优生优育领域有相关诊断产品,如抗缪勒氏管激素(AMH)测定试剂盒(化学发光 法)、人运动神经元存活基因1(SMN1)检测试剂盒(PCR-熔解曲线法)等。 (文章来源:每日经济新闻) ...